Phio Pharmaceuticals(PHIO) Shares Soar 52.48% on Positive Skin Cancer Trial Results

Phio Pharmaceuticals(PHIO) shares surged by 52.48%, reaching their highest level since January 2025, with an intraday gain of 170.30%.

Phio Pharmaceuticals' recent stock price surge can be attributed to several key developments in their skin cancer treatment trials. The company received positive safety recommendations to advance the dose escalation in their PH-762 skin cancer study, which has bolstered investor confidence. Additionally, Phio Pharmaceuticals reported promising results from their Phase 1b trial, achieving a 100% pathological cure rate in early trials for skin cancer. These developments, along with the approval to escalate dosing in the Phase 1b trial after the third cohort showed no serious adverse effects, have contributed to significant stock price increases.

Phio's innovative approach using INTASYL technology to enhance immune response against tumor cells, specifically targeting proteins like PD-1 and BRD4, further supports the bullish outlook. This technology is designed to improve the body's natural defenses against cancer, making it a promising avenue for future treatments. The positive results from the Phase 1b trial, which showed no serious adverse effects, have been particularly encouraging for investors, as it indicates that the treatment is not only effective but also safe for patients.

Overall, the combination of positive safety recommendations, promising trial results, and innovative technology has created a favorable environment for Phio Pharmaceuticals. As the company continues to advance its skin cancer treatment trials, investors are likely to remain optimistic about its future prospects. The recent developments have not only validated the company's approach but also highlighted its potential to revolutionize skin cancer treatment. With a strong focus on innovation and safety, Phio Pharmaceuticals is well-positioned to capitalize on these advancements and continue to drive growth in the pharmaceutical industry.